Use of population pharmacokinetic modeling to characterize intramuscular pharmacokinetics for ziprasidone in schizophrenic patients

Mujeeb Shad, S. H. Preskorn, J. Miceli, K. Wilner

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: To characterize the pharmacokinetics (PK) of the rapid-acting intramuscular (IM) formulation of the novel antipsychotic ziprasidone in schizophrenic patients. Methods: Building upon a population PK model established from data-rich, single-dose studies performed in healthy subjects, the multiple-dose disposition of ziprasidone was characterized in patients receiving ziprasidone IM dose of 5mg (n=6), 10mg (n=6), and 20 mg (n=6) administered four times daily for three days. PK sampling was limited to 12 samples on Day 1 and 14 on Day 3. Results: The results were consistent with predictions from single dose, showing attainment of peak exposure within approx 30 min, dose related increases in exposure, and little drug accumulation. Conclusions: The approach used here demonstrated that population PK modeling is a useful tool in understanding drug disposition where PK sampling is limited. Ziprasidone IM has a predictable, linear PK profile. Therapeutic plasma levels are attained rapidly.

Original languageEnglish (US)
Pages (from-to)171
Number of pages1
JournalClinical Pharmacology and Therapeutics
Volume65
Issue number2
StatePublished - 1999
Externally publishedYes

Fingerprint

Pharmacokinetics
Population
Pharmaceutical Preparations
Antipsychotic Agents
ziprasidone
Healthy Volunteers
Therapeutics

ASJC Scopus subject areas

  • Pharmacology

Cite this

Use of population pharmacokinetic modeling to characterize intramuscular pharmacokinetics for ziprasidone in schizophrenic patients. / Shad, Mujeeb; Preskorn, S. H.; Miceli, J.; Wilner, K.

In: Clinical Pharmacology and Therapeutics, Vol. 65, No. 2, 1999, p. 171.

Research output: Contribution to journalArticle

@article{61ca8b917a26485b834ff023010086df,
title = "Use of population pharmacokinetic modeling to characterize intramuscular pharmacokinetics for ziprasidone in schizophrenic patients",
abstract = "Objective: To characterize the pharmacokinetics (PK) of the rapid-acting intramuscular (IM) formulation of the novel antipsychotic ziprasidone in schizophrenic patients. Methods: Building upon a population PK model established from data-rich, single-dose studies performed in healthy subjects, the multiple-dose disposition of ziprasidone was characterized in patients receiving ziprasidone IM dose of 5mg (n=6), 10mg (n=6), and 20 mg (n=6) administered four times daily for three days. PK sampling was limited to 12 samples on Day 1 and 14 on Day 3. Results: The results were consistent with predictions from single dose, showing attainment of peak exposure within approx 30 min, dose related increases in exposure, and little drug accumulation. Conclusions: The approach used here demonstrated that population PK modeling is a useful tool in understanding drug disposition where PK sampling is limited. Ziprasidone IM has a predictable, linear PK profile. Therapeutic plasma levels are attained rapidly.",
author = "Mujeeb Shad and Preskorn, {S. H.} and J. Miceli and K. Wilner",
year = "1999",
language = "English (US)",
volume = "65",
pages = "171",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Use of population pharmacokinetic modeling to characterize intramuscular pharmacokinetics for ziprasidone in schizophrenic patients

AU - Shad, Mujeeb

AU - Preskorn, S. H.

AU - Miceli, J.

AU - Wilner, K.

PY - 1999

Y1 - 1999

N2 - Objective: To characterize the pharmacokinetics (PK) of the rapid-acting intramuscular (IM) formulation of the novel antipsychotic ziprasidone in schizophrenic patients. Methods: Building upon a population PK model established from data-rich, single-dose studies performed in healthy subjects, the multiple-dose disposition of ziprasidone was characterized in patients receiving ziprasidone IM dose of 5mg (n=6), 10mg (n=6), and 20 mg (n=6) administered four times daily for three days. PK sampling was limited to 12 samples on Day 1 and 14 on Day 3. Results: The results were consistent with predictions from single dose, showing attainment of peak exposure within approx 30 min, dose related increases in exposure, and little drug accumulation. Conclusions: The approach used here demonstrated that population PK modeling is a useful tool in understanding drug disposition where PK sampling is limited. Ziprasidone IM has a predictable, linear PK profile. Therapeutic plasma levels are attained rapidly.

AB - Objective: To characterize the pharmacokinetics (PK) of the rapid-acting intramuscular (IM) formulation of the novel antipsychotic ziprasidone in schizophrenic patients. Methods: Building upon a population PK model established from data-rich, single-dose studies performed in healthy subjects, the multiple-dose disposition of ziprasidone was characterized in patients receiving ziprasidone IM dose of 5mg (n=6), 10mg (n=6), and 20 mg (n=6) administered four times daily for three days. PK sampling was limited to 12 samples on Day 1 and 14 on Day 3. Results: The results were consistent with predictions from single dose, showing attainment of peak exposure within approx 30 min, dose related increases in exposure, and little drug accumulation. Conclusions: The approach used here demonstrated that population PK modeling is a useful tool in understanding drug disposition where PK sampling is limited. Ziprasidone IM has a predictable, linear PK profile. Therapeutic plasma levels are attained rapidly.

UR - http://www.scopus.com/inward/record.url?scp=0012199071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0012199071&partnerID=8YFLogxK

M3 - Article

VL - 65

SP - 171

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 2

ER -